文献速递间质性肺疾病

间质性肺疾病的转录组学:系统综述与荟萃分析

Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.
PubMed 文献 · Eur Respir J · 2025-06-05

该研究采用个体参与者数据方法对纤维性间质性肺疾病转录组研究进行系统综述与荟萃分析,整合24项研究1459例样本建立分类模型,并在8项研究308例样本中验证,识别出可区分特发性肺纤维化等亚型及鉴别不同纤维性间质性肺疾病的稳健转录组特征。

要点

  • 转录组特征可高精度区分IPF、HP、iNSIP和SSc-ILD与对照,验证集AUC 0.91–0.99。
  • 首次发现可鉴别IPF与HP同其他纤维性ILD的稳健转录组特征,AUC分别为0.71和0.76。
  • 无监督学习识别出与FVC和DLCO %pred降低相关的分子内型。

核心结论

  • 呈现迄今首个纤维性间质性肺疾病转录组系统综述与最大规模荟萃分析,识别出具有临床相关性的可重复转录组特征。

研究设计与样本

  • 系统综述与荟萃分析,采用个体参与者数据方法,纳入成人间质性肺疾病人源样本的批量转录组研究,排除聚焦单一细胞群体的研究。
  • 从43项研究提取患者级数据与表达矩阵,用多变量整合算法建立间质性肺疾病分类模型。

主要发现

  • 利用24项研究1459例样本识别出IPF、HP、iNSIP和SSc-ILD相对对照的转录组特征,并在8项研究308例样本中验证。
  • 验证集AUC:IPF 0.99(95%CI 0.99–1.00)、HP 0.91(95%CI 0.84–0.99)、NSIP 0.94(95%CI 0.88–0.99)、SSc-ILD 0.98(95%CI 0.93–1.00)。
  • 荟萃分析首次识别出区分IPF(AUC 0.71,95%CI 0.63–0.79)和HP(AUC 0.76,95%CI 0.63–0.89)与其他纤维性间质性肺疾病的稳健肺转录组特征。
  • 无监督学习算法识别出与用力肺活量和一氧化碳弥散量占预计值百分比降低相关的间质性肺疾病推定分子内型。
  • 转录组特征反映基因表达中细胞特异性和疾病特异性变化。

临床怎么用

  • 转录组分类模型在验证集中对IPF、HP、iNSIP和SSc-ILD相对对照具有高判别力,提示可用于辅助亚型识别。
  • IPF和HP与其他纤维性间质性肺疾病的鉴别AUC中等(0.71和0.76),临床用于鉴别诊断时需结合其他信息。
  • 与FVC和DLCO %pred降低相关的分子内型可能有助于理解疾病异质性,但尚需进一步验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gene expression (transcriptomics) studies have revealed potential mechanisms of interstitial lung disease, yet sample sizes of studies are often limited and between-subtype comparisons are scarce. The aim of this study was to identify and validate consensus transcriptomic signatures of interstitial lung disease subtypes. METHODS: We performed a systematic review and meta-analysis of fibrotic interstitial lung disease transcriptomics studies using an individual participant data approach. We included studies examining bulk transcriptomics of human adult interstitial lung disease samples and excluded those focusing on individual cell populations. Patient-level data and expression matrices were extracted from 43 studies and integrated using a multivariable integrative algorithm to develop interstitial lung disease classification models. RESULTS: Using 1459 samples from 24 studies, we identified transcriptomic signatures for idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, idiopathic nonspecific interstitial pneumonia and systemic sclerosis-associated interstitial lung disease against control samples, which were validated on 308 samples from eight studies (idiopathic pulmonary fibrosis area under receiver operating curve (AUC) 0.99, 95% CI 0.99-1.00; hypersensitivity pneumonitis AUC 0.91, 95% CI 0.84-0.99; nonspecific interstitial pneumonia AUC 0.94, 95% CI 0.88-0.99; systemic sclerosis-associated interstitial lung disease AUC 0.98, 95% CI 0.93-1.00). Significantly, meta-analysis allowed us to identify, for the first time, robust lung transcriptomics signatures to discriminate idiopathic pulmonary fibrosis (AUC 0.71, 95% CI 0.63-0.79) and hypersensitivity pneumonitis (AUC 0.76, 95% CI 0.63-0.89) from other fibrotic interstitial lung disease, and unsupervised learning algorithms identified putative molecular endotypes of interstitial lung disease associated with decreased forced vital capacity and diffusing capacity of the lungs for carbon monoxide % predicted. Transcriptomics signatures were reflective of both cell-specific and disease-specific changes in gene expression. CONCLUSION: We present the first systematic review and largest meta-analysis of fibrotic interstitial lung disease transcriptomics to date, identifying reproducible transcriptomic signatures with clinical relevance.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. He D, Guler SA, Shannon CP, et al. Transcriptomics of interstitial lung disease: a systematic review and meta-analysis. Eur Respir J. 2025. PMID: 39603671. doi:10.1183/13993003.01070-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。